Growth hormone-secreting tumors: Genetic aspects and data from animal models

Neuroendocrinology

Volumn 83, Issue 3-4, 2006, Pages 166-178

  Lytras, Aristides ^a   Tolis, George ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Carney complex; Germline mutations; Growth hormone secreting tumors; Hereditary pituitary tumors; Isolated familial somatotropinomas; Menin; Multiple endocrine neoplasia type 1; Tumor suppressor gene

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; GROWTH HORMONE; HISTONE DEACETYLASE; METHIONINE; NUCLEAR PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARCINOGENESIS; CARNEY COMPLEX; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 11Q; CHROMOSOME 17; CHROMOSOME 2P; CNC GENE; CONFERENCE PAPER; CONTROLLED STUDY; GENE; GENE INACTIVATION; GENE MUTATION; HETEROZYGOTE; HYPOPHYSIS TUMOR; IFS GENE; INSULINOMA; ISOLATED FAMILIAL SOMATOTROPINOMA; MEN1 GENE; MOUSE; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PARATHYROID ADENOMA; PRIORITY JOURNAL; PROLACTINOMA; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ANIMALS; CHROMOSOME MAPPING; CYCLIC AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; ENDOCRINE GLAND NEOPLASMS; HUMAN GROWTH HORMONE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEOPLASTIC SYNDROMES, HEREDITARY; NEUROENDOCRINE TUMORS; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS; SYNDROME;

EID: 33750070645     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095525     Document Type: Conference Paper

References (94)

1. Lania A, Mantovani G, Spada A: Genetics of pituitary tumors: focus on G-protein mutations. Exp Biol Med 2003;228:1004-1017.
2. Marx SJ, Simonds WF: Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr Rev 2005;26:615-661.
3. sα mutations in the McCune-Albright syndrome and in isolated endocrine tumors. J Clin Endocrinol Metab 2004;89:3007-3009.
4. Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
5. Knudson AG: Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1:157-162.
6. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
7. Guo SS, Sawicki MP: Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol Endocrinol 2001;15:1653-1664.
8. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-407.
9. Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, Spiegel AM, Collins FS: A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 2001;98:1118-1123.
10. Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, Chandrasekharappa SC: Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 1998;95:1630-1634.
11. Pannet AAJ, Thakker RV: Somatic mutations in MEN type 1 tumors, consistent with the Knudson 'two hit' hypothesis. J Clin Endocrinol Metab 2001;86:4371-4374.
12. Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX: Heterozygous MEN1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol 2003;17:1880-1892.
13. Biondi CA, Gartside MG, Waring P, Loffler KA, Stark MS, Magnuson MA, Kay GF, Hayward NK: Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol 2004;24:3125-3131.
14. Fritz A, Walch A, Piotrowska K, Rosemann M, Schaffer E, Weber K, Timper A, Wildner G, Graw J, Hofler H, Atkinson MJ: Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 2002;62:3048-3051.
15. Piotrowska K, Pellegata NS, Rosemann M, Fritz A, Graw J, Atkinson MJ: Mapping of a novel MEN-like syndrome locus to rat chromosome 4. Mamm Genome 2004;15:135-141.
16. Kim H, Lee JE, Cho EJ, Liu JO, Youn HD: Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3a-histone deacetylase complex. Cancer Res 2003;63:6135-6139.
17. Yaguchi H, Ohkura N, Takahashi M, Nagamura Y, Kitabayashi I, Tsukada T: Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol Cell Biol 2004;24:6569-6580.
18. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, Meyerson M: Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 2004;13:587-597.
19. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL: Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999;96:143-152.
20. Kaji H, Canaff L, Goltzman D, Hendy GN: Cell cycle regulation of menin expression. Cancer Res 1999;59:5097-5101.
21. Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D'Andrea AD, Hua X: Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 2003;63:4204-4210.
22. Sukhodolets KE, Hickman AB, Agarwal SK, Sukhodolets MV, Obungu VH, Novotny EA, Crabtree JS, Chandrasekharappa SC, Collins FS, Spiegel AM, Burns AL, Marx SJ: The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol Cell Biol 2003;23:493-509.
23. Sowa H, Kaji H, Canaff L, Hendy GN, Tsukamoto T, Yamaguchi T, Miyazono K, Sugimoto T, Chihara K: Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage. J Biol Chem 2003;278:21058-21069.
24. Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W, Cleary ML: Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 2004;24:5639-5649.
25. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, Gibbs D, Hua X, Roeder RG, Meyerson M, Hess JL: Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci USA 2005;102:749-754.
26. La P, Silva AC, Hou Z, Wang H, Schnepp RW, Yan N, Shi Y, Hua X: Direct binding of DNA by tumor suppressor menin. J Biol Chem 2004;279:49045-49054.
27. Ernst P, Wang J, Huang M, Goodman RH, Korsmeyer SJ: MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Mol Cell Biol 2001;21:2249-2258.
28. Roberts CW, Orkin SH: The SWI/SNF complex - chromatin and cancer. Nat Rev Cancer 2004;4:133-142.
29. Rozenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J, Nakamura T, Croce CM, Mazo A, Canaani E: The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci USA 1998;95:4152-4157.
30. Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM, Maris JM: Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999;18:4948-4957.
31. Herbst RA, Gutzmer R, Matiaske F, Mommert S, Casper U, Kapp A, Weiss J: Identification of two distinct deletion targets at 11q23 in cutaneous malignant melanoma. Int J Cancer 1999;80:205-209.
32. Sherr CJ: Principles of tumor suppression. Cell 2004;116:235-246.
33. Virolle T, Monthouel MN, Djabari Z, Ortonne JP, Meneguzzi G, Aberdam D: Three activator protein-1-binding sites bound by the Fra-2.JunD complex cooperate for the regulation of murine laminin alpha3A (lama3A) promoter activity by transforming growth factor-beta. J Biol Chem 1998;273:17318-17325.
34. 1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. J Biol Chem 1999;274:12933-12938.
35. Liberati NT, Datto MB, Frederick JP, Shen X, Wong C, Rougier-Chapman EM, Wang XF: Smads bind directly to the Jun family of AP-1 transcription factors. Proc Natl Acad Sci USA 1999;96:4844-4849.
36. Gobl AE, Berg M, Lopez-Egido JR, Oberg K, Skogseid B, Westin G: Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochim Biophys Acta 1999;1447:51-56.
37. Yazgan O, Pfarr CM: Differential binding of the menin tumor suppressor protein to JunD isoforms. Cancer Res 2001;61:916-920.
38. Agarwal SK, Novotny EA, Crabtree JS, Weitzman JB, Yaniv M, Burns AL, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ: Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci USA 2003;100:10770-10775.
39. Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN: Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signalling. Proc Natl Acad Sci USA 2001;98:3837-3842.
40. Gallo A, Cuozzo C, Esposito I, Maggiolini M, Bonofiglio D, Vivacqua A, Garramone M, Weiss C, Bohmann D, Musti AM: Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. Oncogene 2002;21:6434-6445.
41. Hirai SI, Ryseck RP, Mechta F, Bravo R, Yaniv M: Characterization of junD: a new member of the jun proto-oncogene family. EMBO J 1989;8:1433-1439.
42. Ryder K, Lanahan A, Perez-Albuerne E, Nathans D: Jun-D: a third member of the jun gene family. Proc Natl Acad Sci USA 1989;86:1500-1503.
43. Hartl M, Hutchins JT, Vogt PK: The chicken junD gene and its product. Oncogene 1991;6:1622-1631.
44. Theill LE, Karin M: Transcriptional control of GH expression and anterior pituitary development. Endocr Rev 1993;14:670-689.
45. Zhou Y, Sun H, Danila DC, Johnson SR, Sigai DP, Zhang X, Klibanski A: Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling. Mol Endocrinol 2000;14:2066-2075.
46. Alexander JM, Bikkal HA, Zervas NT, Laws ER Jr, Klibanski A: Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas. J Clin Endocrinol Metab 1996;81:783-790.
47. Namihira H, Sato M, Murao K, Cao WM, Matsubara S, Imachi H, Niimi M, Dobashi H, Wong NC, Ishida T: The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. J Mol Endocrinol 2002;29:297-304.
48. Lacerte A, Lee EH, Reynaud R, Canaff L, De Guise C, Devost D, Ali S, Hendy GN, Lebrun JJ: Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and menin. Mol Endocrinol 2004;18:1558-1569.
49. Pellegrini I, Barlier A, Gunz G, Figarella-Branger D, Enjalbert A, Grisoli F, Jaquet P: Pit-1 gene expression in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab 1994;79:189-196.
50. Schnepp RW, Mao H, Sykes SM, Zong WX, Silva A, La P, Hua X: Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem 2004;279:10685-10691.
51. Yaguchi H, Ohkura N, Tsukada T, Yamaguchi K: Menin, the multiple endocrine neoplasia type 1 gene product, exhibits GTP-hydrolyzing activity in the presence of the tumor metastasis suppressor nm23. J Biol Chem 2002;277:38197-38204.
52. Stratakis CA, Kirschner LS, Carney JA: Genetics of endocrine disease: clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001;86:4041-4046.
53. Groussin L, Kirschner LS, Vincent-Dejean C, Perlemoine K, Jullian E, Delemer B, Zacharieva S, Pignatelli D, Carney JA, Luton JP, Bertagna X, Stratakis CA, Bertherat J: Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1a (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet 2002;71:1433-1442.
54. Bossis I, Voutetakis A, Bei T, Sandrini F, Griffin KJ, Stratakis CA: Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr Relat Cancer 2004;11:265-280.
55. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
56. Veugelers M, Wilkes D, Burton K, McDermott DA, Song Y, Goldstein MM, La Perle K, Vaughan CJ, O'Hagan A, Bennett KR, Meyer BJ, Legius E, Karttunen M, Norio R, Kaariainen H, Lavyne M, Neau JP, Richter G, Kirali K, Farnsworth A, Stapleton K, Morelli P, Takanashi Y, Bamforth JS, Eitelberger F, Noszian I, Manfroi W, Powers J, Mochizuki Y, Imai T, Ko GT, Driscoll DA, Goldmuntz E, Edelberg JM, Collins A, Eccles D, Irvine AD, McKnight GS, Basson CT: Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkarla haploinsufficient mice. Proc Natl Acad Sci USA 2004;101:14222-14227.
57. Kirschner LS, Kusewitt DF, Matyakhina L, Towns WH 2nd, Carney JA, Westphal H, Stratakis CA: A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res 2005;65:4506-4514.
58. Yamasaki H, Mizusawa N, Nagahiro S, Yamada S, Sano T, Itakura M, Yoshimoto K: GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23-24. Clin Endocrinol (Oxf) 2003;58:464-470.
59. Kaltsas GA, Kola B, Borboli N, Morris DG, Gueorguiev M, Swords FM, Czirjak S, Kirschner LS, Stratakis CA, Korbonits M, Grossman AB: Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin Endocrinol (Oxf) 2002;57:443-448.
60. Matyakhina L, Pack S, Kirschner LS, Pak E, Mannan P, Jaikumar J, Taymans SE, Sandrini F, Carney JA, Stratakis CA: Chromosome 2 (2p16) abnormalities in Carney complex tumours. J Med Genet 2003;40:268-277.
61. Amieux PS, Howe DG, Knickerbocker H, Lee DC, Su T, Laszlo GS, Idzerda RL, McKnight GS: Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo. J Biol Chem 2002;277:27294-27304.
62. Amieux PS, McKnight GS: The essential role of RIα in the maintenance of regulated PKA activity. Ann N Y Acad Sci 2002;968:75-95.
63. Tanaka C, Kimura T, Yang P, Moritani M, Yamaoka T, Yamada S, Sano T, Yoshimoto K, Itakura M: Analysis of loss of heterozygosity on chromosome 11 and infrequent inactivation of the MEN1 gene in sporadic pituitary adenomas. J Clin Endocrinol Metab 1998;83:2631-2634.
64. Kaltsas GA, Besser GM, Grossman AB: Diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458-511.
65. Tanaka C, Yoshimoto K, Yamada S, Nishioka H, Ii S, Moritani M, Yamaoka T, Itakura M: Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese. J Clin Endocrinol Metab 1998;83:960-965.
66. Asa SL, Somers K, Ezzat S: The MEN-1 gene is rarely down-regulated in pituitary adenomas. J Clin Endocrinol Metab 1998;83:3210-3212.
67. Satta MA, Korbonits M, Jacobs RA, Bolden-Dwinfour DA, Kaltsas GA, Vangeli V, Adams E, Fahlbusch R, Grossman AB: Expression of menin gene mRNA in pituitary tumours. Eur J Endocrinol 1999;140:358-361.
68. Wrocklage C, Gold H, Hackl W, Buchfelder M, Fahlbusch R, Paulus W: Increased menin expression in sporadic pituitary adenomas. Clin Endocrinol (Oxf) 2002;56:589-594.
69. Theodoropoulou M, Cavallari I, Barzon L, D'Agostino DM, Ferro T, Arzberger T, Grubler Y, Schaaf L, Losa M, Fallo F, Ciminale V, Stalla GK, Pagotto U: Differential expression of menin in sporadic pituitary adenomas. Endocr Relat Cancer 2004;11:333-344.
70. Asa SL, Ezzat S: The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998;19:798-827.
71. Gadelha MR, Une KN, Rohde K, Vaisman M, Kineman RD, Frohman LA: Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J Clin Endocrinol Metab 2000;85:707-714.
72. Stratakis CA, Kirschner LS: Isolated familial somatotropinomas: does the disease map to 11q13 or to 2p16? J Clin Endocrinol Metab 2000;85:4920-4921.
73. Gadelha MR, Rhode K, Kineman RD, Frohman LA: Authors' response: isolated familial somatotropinomas: does the disease map to 11q13 or to 2p16? J Clin Endocrinol Metab 2000;85:4921.
74. Luccio-Camelo DC, Une KN, Ferreira RE, Khoo SK, Nickolov R, Bronstein MD, Vaisman M, Teh BT, Frohman LA, Mendonca BB, Gadelha MR: A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur J Endocrinol 2004;150:643-648.
75. Soares BS, Eguchi K, Frohman LA: Tumor deletion mapping on chromosome 11q13 in eight families with isolated familial somatotropinoma and in 15 sporadic somatotropinomas. J Clin Endocrinol Metab 2005;90:6580-6587.
76. Vrontakis ME, Peden LM, Duckworth ML, Friesen HG: Isolation and characterization of a complementary DNA (galanin) clone from estrogen-induced pituitary tumor messenger RNA. J Biol Chem 1987;262:16756-16758.
77. Perumal P, Vrontakis ME: Transgenic mice over-expressing galanin exhibit pituitary adenomas and increased secretion of galanin, prolactin and growth hormone. J Endocrinol 2003;179:145-154.
78. Moore JP Jr, Cai A, Maley BE, Jennes L, Hyde JF: Galanin within the normal and hyperplastic anterior pituitary gland: localization, secretion, and functional analysis in normal and human growth hormone-releasing hormone transgenic mice. Endocrinology 1999;140:1789-1799.
79. Invitti C, Pecori Giraldi F, Dubini A, Moroni P, Losa M, Piccoletti R, Cavagnini F: Galanin is released by adrenocorticotropin-secreting pituitary adenomas in vivo and in vitro. J Clin Endocrinol Metab 1999;84:1351-1356.
80. Hammer RE, Brinster RL, Rosenfeld MG, Evans RM, Mayo KE: Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature 1985;315:413-416.
81. Mayo KE, Hammer RE, Swanson LW, Brinster RL, Rosenfeld MG, Evans RM: Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Mol Endocrinol 1988;2:606-612.
82. Lu X, Magrane G, Yin C, Louis DN, Gray J, Van Dyke T: Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol Cell Biol 2001;21:6017-6030.
83. Trovato M, Ulivieri A, Dominici R, Ruggeri RM, Vitarelli E, Benvenga S, Barresi G, Trimarchi F, Brunetti E, Vecchione A, Andreoli M, Sciacchitano S: Clinico-pathological significance of cell-type-specific loss of heterozygosity on chromosome 7q21: analysis of 318 microdissected thyroid lesions. Endocr Relat Cancer 2004;11:365-376.
84. MacDonald HR, Wevrick R: The necdin gene is deleted in Prader-Willi syndrome and is imprinted in human and mouse. Hum Mol Genet 1997;6:1873-1878.
85. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC, Wu CW: Genomewide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 2000;60:3884-3892.
86. Tomlinson IPM, Bodmer WF: Chromosome 11q in sporadic colorectal carcinoma: patterns of allele loss and their significance for tumorigenesis. J Clin Pathol 1996;49:386-390.
87. Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD: A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002;62:3925-3928.
88. Kitayama Y, Igarashi H, Sugimura H: Different vulnerability among chromosomes to numerical instability in gastric carcinogenesis: stage-dependent analysis by FISH with the use of microwave irradiation. Clin Cancer Res 2000;6:3139-3146.
89. Libutti SK, Crabtree JS, Lorang D, Burns AL, Mazzanti C, Hewitt SM, O'Connor S, Ward JM, Emmert-Buck MR, Remaley A, Miller M, Turner E, Alexander HR, Arnold A, Marx SJ, Collins FS, Spiegel AM: Parathyroid gland-specific deletion of the mouse MEN1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res 2003;63:8022-8028.
90. Heppner C, Bilimoria KY, Agarwal SK, Rester M, Whitty LJ, Guru SC, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL: The tumor suppressor protein menin interacts with NF-κB proteins and inhibits NF-κB-mediated transactivation. Oncogene 2001;20:4917-4925.
91. Lemmens IH, Forsberg L, Pannett AA, Meyen E, Piehl F, Turner JJ, Van de Ven WJ, Thakker RV, Larsson C, Kas K: Menin interacts directly with the homeobox-containing protein Pem. Biochem Biophys Res Commun 2001;286:426-431.
92. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA: Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Mol Genet 2000;9:3037-3046.
93. Lania AG, Mantovani G, Ferrero S, Pellegrini C, Bondioni S, Peverelli E, Braidotti P, Locatelli M, Zavanone ML, Ferrante E, Bosari S, Beck-Peccoz P, Spada A: Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase A regulatory subunit 1A protein. Cancer Res 2004;64:9193-9198.
94. Frohman LA, Eguchi K: Familial acromegaly. Growth Horm IGF Res 2004;14(suppl A):S90-S96.